Meeting
2023 ASCO Annual Meeting
Risk of severe toxicity from topical fluoropyrimidine treatment in patients carrying DPYD variant alleles.
Authors
Javier Granados
University of Michigan, Ann Arbor, MI
Javier Granados , Amy Pasternak , Norah Lynn Henry , Vaibhav Sahai , Daniel Louis Hertz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Palliative Care and Symptom Management
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 12123)
DOI
10.1200/JCO.2023.41.16_suppl.12123
Abstract #
12123
Poster Bd #
491
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Quality Care Symposium
Sustainability and clinical outcomes of routine screening for pathogenic DPYD gene variants prior to fluoropyrimidine (FP) chemotherapy for gastrointestinal (GI) cancer.
First Author: Gabriel A. Brooks
Poster
2020 Gastrointestinal Cancers Symposium
DPYD gene polymorphisms in patients with gastrointestinal tumors receiving chemotherapy with 5-fluorouracil.
First Author: Oleg Ivanovich Kit
Poster
2023 ASCO Quality Care Symposium
Implementing a high-reliability, system-wide program for pre-emptive DPD deficiency testing for patients planned for a systemic fluoropyrimidine.
First Author: Garrett Rompelman
Poster
2023 ASCO Annual Meeting
Real-world experience of an in-house dihydropyrimidine dehydrogenase (DPYD) genotype test to guide fluoropyrimidine (FP) dosing at a multisite cancer hospital.
First Author: Jai Narendra Patel